

Product No. F-2153 Lot 044H0296

Monoclonal Anti-Human Fibroblast Growth Factor-4 IgG Fraction of Mouse Ascites Fluid

Clone 19805.11

Monoclonal Anti-Human Fibroblast Growth Factor-4 (FGF-4) (IgG1 isotype) is purified from the 19805.11 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice. Human, recombinant fibroblast growth factor-4 (rhFGF-4), expressed in *E. coli*, was used as immunogen. The antibody is purified by Protein A affinity chromatography. Monoclonal Anti-FGF-4 is provided lyophilized from phosphate buffered saline, pH 7.4, to which no preservatives are added.

Description

Fibroblast growth factor-4 is a member of the FGF family, a group of 7 homologous polypeptides that act upon a variety of cells and produce biological actions that may include cell proliferation, migration and differentiation.^{1,2} FGF-4, also known as oncogene products hst-1 and K-FGF, has strong transforming potential and is a potent angiogenic factor, being expressed in several highly vascularized tumors.^{3,4} Anti-Human FGF-4 neutralizes the bioactivity of recombinant, human FGF-4 but not that of bovine or human, recombinant FGF-Basic, bovine or human, recombinant FGF-Acidic, human, recombinant FGF-5, human, recombinant FGF-6, or human, recombinant β-ECGF. In indirect ELISA and immunoblotting, this antibody displays no cross-reactivity with bovine or human, recombinant FGF-Basic, bovine or human, recombinant FGF-Acidic, or human, recombinant β-ECGF.

Performance

Anti-Human FGF-4 is tested for its ability to neutralize the bioactivity of rhFGF-4 in a cell proliferation assay using FGF-4 responsive NR6-3T3 fibroblasts.⁵ The ND₅₀ of the antibody is defined as the concentration of antibody resulting in a one-half maximal inhibition of bioactivity of rhFGF-4, which is present at five times its own EC₅₀ (the concentration of rhFGF-4 producing a one-half maximal bioactivity without antibody). In this bioassay, rhFGF-4 was pre-incubated with various dilutions of the antibody for

1 hour at 37°C in a 96-well microtiter plate. Then, the antigen-antibody mixtures were added to quiescent confluent NR6-3T3 cultures in 0.1 ml containing 0.5 ng/ml rhFGF-4. This was incubated for 20 hours at 37°C in a 5% $\rm CO_2$ humidified incubator and then pulsed for 2 hours with $^3\rm H$ -thymidine. Cells were harvested onto glass filters and the $^3\rm H$ -thymidine incorporation into DNA was measured.

Product Information

Mass/vial: 0.5 mg

Immunogen: Human, recombinant FGF-4

Isotype: Mouse IgG1

Formulation: Lyophilized from PBS without

additives

Endotoxin: <10 ng/vial by LAL method

Bioactivity: $ND_{50} = 7.6 \,\mu \text{g/ml}$

Indirect ELISA: 0.5 µg/ml detects 1.5 ng/well of

rhFGF-4

Indirect

Immunoblotting: 1 µg/ml antibody detects rhFGF-4

at 20 ng/lane under both reducing

and non-reducing conditions

Sterility: 0.2 μ m-filtered, aseptic fill

Reconstitution and Use

To one vial of lyophilized powder, add 1 ml of sterile-filtered PBS to produce a 0.5 mg/ml stock solution of Anti-Human FGF-4. If aseptic technique is used, no further filtration should be needed for use in cell culture environments.

Storage

Prior to reconstitution, store at -20°C for 6 months. Reconstituted product may be stored at 0-5°C for up to one month. For prolonged storage, freeze in working aliquots at -20°C. Avoid repeated freezing and thawing.

References

- 1. Gospodarowicz, D., The Fibroblast Growth Factor Family, Baird, A, and Klagsbrun, M., (eds.), Ann. NY Acad. Sci., **638**, 1 (1991).
- 2. Burgess, W., and Maciag, T., Ann. Rev. Biochem., **58**, 575 (1989).
- 3. Yoshida, T., et al., Ann. NY Acad. Sci., **638**, 27 (1991).
- 4. Theillet, C., et al., Oncogene, 4, 915 (1989).
- 5. Rizzino, A., et al., Cancer Res., 48, 4266 (1988).

Prepared for Sigma.

Sigma warrants that its products conform to the information contained in this and other Sigma publications. Purchaser must determine the suitability of the product for its particular use. See reverse side of invoice or packing slip for additional terms and conditions of sale.

Issued 06/94.